Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Price:
90.72
USD
-1.03%
Market Cap:
$5.5B
Relative Value
The Relative Value of one
MIRM
stock under the Base Case scenario is
66.39
USD.
Compared to the current market price of 90.72 USD,
Mirum Pharmaceuticals Inc
is
Overvalued by 27%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MIRM
Relative Value
Base Case
66.39
USD
Overvaluation 27%
Multiples Across Competitors
MIRM Competitors Multiples
Mirum Pharmaceuticals Inc Competitors
Mirum Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
5.5B USD | 9.2 | -205 | 2 617.9 | -249.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.6B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.1B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.3B USD | 9.7 | 29.4 | 22.2 | 23.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.7B AUD | 3.1 | 33.9 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.5B EUR | 10.3 | 33 | 35.6 | 36.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
